Lux Biosciences

Lux Biosciences is a biotechnology company developing medicines for the treatment of ophthalmic diseases.

Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.